According to TipRanks, Biegler is an analyst with an average return of -3.3% and a 31.11% success rate. Biegler covers the Healthcare sector, focusing on stocks such as IDEAYA Biosciences, Fate Therapeutics, and Blueprint Medicines.
In addition to Oppenheimer, IDEAYA Biosciences also received a Buy from Robert W. Baird’s Joel Beatty in a report issued today. However, yesterday, Stifel Nicolaus downgraded IDEAYA Biosciences (NASDAQ: IDYA) to a Hold.
The company has a one-year high of $28.00 and a one-year low of $8.14. Currently, IDEAYA Biosciences has an average volume of 299.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
Read More on IDYA:
- Analysts Offer Insights on Financial Companies: PotlatchDeltic (PCH), Reinsurance Group (RGA) and Local Bounti Corporation (LOCL)
- Analysts’ Opinions Are Mixed on These Technology Stocks: MACOM Technology Solutions Holdings (MTSI), Teledyne Technologies (TDY) and Snowflake (SNOW)
- Analysts Conflicted on These Healthcare Names: Horizon Therapeutics (HZNP), Ironwood Pharma (IRWD) and Applied Therapeutics (APLT)
- Analysts Offer Insights on Consumer Goods Companies: Home Depot (HD), thredUP (TDUP) and Sovos Brands (SOVO)
- Michael Burry’s Fund Exits All Long Stocks Except One